[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR075736A1 - Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa) - Google Patents

Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa)

Info

Publication number
AR075736A1
AR075736A1 ARP100100739A ARP100100739A AR075736A1 AR 075736 A1 AR075736 A1 AR 075736A1 AR P100100739 A ARP100100739 A AR P100100739A AR P100100739 A ARP100100739 A AR P100100739A AR 075736 A1 AR075736 A1 AR 075736A1
Authority
AR
Argentina
Prior art keywords
difluorophenyl
amino
sodium salt
benzoic
cyclopropil
Prior art date
Application number
ARP100100739A
Other languages
English (en)
Inventor
Laurent Debethune
Carrera Francesc Carrera
Gonzalez Nuria Garcia
Masia Xavier Serra
Jane Montserrat Julia
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40903239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075736(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR075736A1 publication Critical patent/AR075736A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a la sal de sodio cristalina hidrosoluble de ácido 2-{[5-ciclopropil-2-{[2-(2,6'-difluorofenil)pirimidin-5-il]amino}benzoico y a sus solvatos farmacéuticamente aceptables, composiciones farmacéuticas, composiciones utiles para artritis reumatoidea, psoriásica, espondilitis anquilosante, etc.
ARP100100739A 2009-03-13 2010-03-11 Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa) AR075736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382033A EP2239256A1 (en) 2009-03-13 2009-03-13 Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor

Publications (1)

Publication Number Publication Date
AR075736A1 true AR075736A1 (es) 2011-04-20

Family

ID=40903239

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100739A AR075736A1 (es) 2009-03-13 2010-03-11 Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa)

Country Status (22)

Country Link
US (1) US8501943B2 (es)
EP (2) EP2239256A1 (es)
JP (1) JP2012520250A (es)
KR (1) KR20110125653A (es)
CN (1) CN102348687B (es)
AR (1) AR075736A1 (es)
AU (1) AU2010223526A1 (es)
CA (1) CA2754801A1 (es)
CL (1) CL2011002215A1 (es)
CO (1) CO6420336A2 (es)
EA (1) EA020218B1 (es)
EC (1) ECSP11011383A (es)
IL (1) IL214518A0 (es)
MX (1) MX2011009148A (es)
NZ (1) NZ594492A (es)
PE (1) PE20120114A1 (es)
SG (1) SG173825A1 (es)
TW (1) TW201032811A (es)
UA (1) UA105788C2 (es)
UY (1) UY32466A (es)
WO (1) WO2010102824A2 (es)
ZA (1) ZA201105742B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2376495A4 (en) 2008-12-08 2012-10-31 Vm Pharma Llc COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP2444088A1 (en) * 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
US20120195933A1 (en) * 2011-01-27 2012-08-02 Ralph Stefan Pharmaceutical compositions comprising tasocitinib
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
MA39286A (fr) 2014-09-17 2016-03-24 Mundipharma International Corporation Ltd Formes cristallines d'inhibiteurs de la tyrosine kinase et leurs sels
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
CN114957650B (zh) * 2022-06-11 2024-05-10 新疆腾域鸿源农业科技有限公司 一种聚天冬氨酸钾的制备方法及其在植物生长促进剂中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225396C (en) 1995-06-21 2003-03-25 Asta Medica Aktiengesellschaft Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
AP2002002387A0 (en) 1999-06-10 2002-03-31 Warner Lambert Co Method of inhibiting amyloid aggregation and imaging amyloid deposits.
WO2002080897A1 (en) 2001-04-05 2002-10-17 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
WO2002102374A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Amine salt of an integrin receptor antagonist
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581478A1 (en) 2002-12-23 2005-10-05 4Sc Ag Dhodh-inhibitors and method for their identification
SE0400234D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
CN1993125A (zh) 2004-05-21 2007-07-04 Uab研究基金会 涉及嘧啶合成抑制剂的组合物和方法
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
CN101043883A (zh) 2004-10-19 2007-09-26 安万特药物公司 (z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2303758B1 (es) 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
WO2008097180A1 (en) 2007-02-06 2008-08-14 Chelsea Therapeutics, Inc. New compounds, methods for their preparation and use thereof
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

Also Published As

Publication number Publication date
WO2010102824A2 (en) 2010-09-16
IL214518A0 (en) 2011-09-27
AU2010223526A1 (en) 2011-08-25
KR20110125653A (ko) 2011-11-21
CL2011002215A1 (es) 2012-03-09
MX2011009148A (es) 2011-09-28
TW201032811A (en) 2010-09-16
EP2239256A1 (en) 2010-10-13
CO6420336A2 (es) 2012-04-16
WO2010102824A3 (en) 2010-11-18
EA020218B1 (ru) 2014-09-30
NZ594492A (en) 2013-11-29
UY32466A (es) 2010-09-30
CN102348687B (zh) 2014-04-02
UA105788C2 (uk) 2014-06-25
EP2406221A2 (en) 2012-01-18
SG173825A1 (en) 2011-09-29
JP2012520250A (ja) 2012-09-06
EA201101301A1 (ru) 2012-04-30
CA2754801A1 (en) 2010-09-16
US8501943B2 (en) 2013-08-06
ECSP11011383A (es) 2011-11-30
PE20120114A1 (es) 2012-02-20
ZA201105742B (en) 2012-04-25
CN102348687A (zh) 2012-02-08
US20120003184A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
AR075736A1 (es) Sal de sodio de acido 5- ciclopropil -2-((2-(2,6- difluorofenil ) pirimidin -5-il) amino) benzoico como inhibidor de dhodh (dihidroorotato deshidrogenasa)
PE20090903A1 (es) Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa
MX2013005533A (es) Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
NZ607845A (en) Besylate salt of a btk inhibitor
MX2012006562A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-( 4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas.
UY33044A (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos
PE20120171A1 (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh
CL2011002918A1 (es) Composicion farmaceutica solida que comprende al inhibidor de quinasa aurora acido 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico, una sal o una forma cristalina del mismo; metodo para prepararla que incluye un proceso de granulacion en humedo.
PA8855501A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
NI200900155A (es) COMPUESTOS DE 2-AMINO PIRIMIDINA. Caso: PC 33441A
MY152281A (en) 4-pyrimidinesulfamide derivative
PH12014502210A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
PE20080175A1 (es) Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico
PT2448933E (pt) Ácido trans-4-[[(5s)-5-[[[3,5- bis(trifluorometil)fenil]metil] (2-metil-2h-tetrazol-5- il)amino]-2,3,4,5-tetra-hidro-7,9-dimetil-1h-1-benzazepin- 1-il]metil]-ciclo-hexanocarboxílico
TN2009000167A1 (en) Crystalline potassium salt of lipoxin a4 analogs
CL2013000929A1 (es) Forma cristalina c de la sal sodica del acido (4-(4-(5-(6-trifluoro metil piridin-3-il-amino) piridin-2-il-) fenil)-ciclohexil)-acetico; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento de un trastorno asociado con la actividad del dagt.
CL2011002213A1 (es) Sal de adicion cristalina de (i) trometamina con (ii) un derivado de acido azabifenilaminobenzoico; composicion farmaceutica que comprende a la sal y otros agentes terapeuticos; combinacion farmaceutica; y su uso para el tratamiento de artritis reumatoide, artritis psoriasica, espondilitis anquilosante, esclerosis multiple, entre otras
RS53419B (en) FORMULATIONS OF DEOXYCHOLINIC ACID AND ITS SALTS
NZ610765A (en) Method for the preparation of high-purity pharmaceutical intermediates
CL2013000578A1 (es) Sal cristalina de sodio del acido (e)-3-[2-(1-{[2-(5-bromo-pririmidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico: sal amorfa;compuestos intermediarios; procedimientos de preparacion; composicion farmaceutica.
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
NZ598693A (en) Maleic acid salt and crystal thereof
FR2984319B1 (fr) Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
PA8786301A1 (es) "un nuevo procedimiento para preparar acido 2-(3-{6-[2(2,4-diclorofenil)-etilamino]-2-metoxipirimidin-4-il}-fenil)-2-metil-propionico"

Legal Events

Date Code Title Description
FA Abandonment or withdrawal